{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:35:40Z","timestamp":1783114540665,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["JP24K19445"],"award-info":[{"award-number":["JP24K19445"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10147-025-02706-4","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:04:08Z","timestamp":1739343848000},"page":"705-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8812-1787","authenticated-orcid":false,"given":"Masatoshi","family":"Kanayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuma","family":"Yoshimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2706_CR1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397\u2013408","journal-title":"Lancet"},{"key":"2706_CR2","first-page":"260","volume":"17","author":"JC Wagner","year":"1960","unstructured":"Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17:260\u2013271","journal-title":"Br J Ind Med"},{"key":"2706_CR3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644","journal-title":"J Clin Oncol"},{"key":"2706_CR4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397:375\u2013386","journal-title":"Lancet"},{"key":"2706_CR5","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","volume":"22","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C et al (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 22:1530\u20131540","journal-title":"Lancet Oncol"},{"key":"2706_CR6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C et al (2022) Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol 33:129\u2013142","journal-title":"Ann Oncol"},{"key":"2706_CR7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"2706_CR8","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/JTO.0b013e3182208e3f","volume":"6","author":"D Rice","year":"2011","unstructured":"Rice D, Rusch V, Pass H et al (2011) Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 6:1304\u20131312","journal-title":"J Thorac Oncol"},{"key":"2706_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257\u2013260","journal-title":"Ann Oncol"},{"key":"2706_CR10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ijrobp.2020.04.040","volume":"107","author":"AT Fairchild","year":"2020","unstructured":"Fairchild AT, Tanksley JP, Tenenbaum JD et al (2020) Interrater reliability in toxicity identification: limitations of current standards. Int J Radiat Oncol Biol Phys 107:996\u20131000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2706_CR11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jtcvs.2017.05.106","volume":"155","author":"A Hirai","year":"2018","unstructured":"Hirai A, Yoneda K, Shimajiri S et al (2018) Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. J Thorac Cardiovasc Surg 155:382-392.e1","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2706_CR12","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41598-019-57321-x","volume":"10","author":"Y Tashima","year":"2020","unstructured":"Tashima Y, Kuwata T, Yoneda K et al (2020) Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung. Sci Rep 10:1243","journal-title":"Sci Rep"},{"key":"2706_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107866","volume":"194","author":"O Bylicki","year":"2024","unstructured":"Bylicki O, Guisier F, Scherpereel A et al (2024) Real-world efficacy and safety of combination nivolumab plus ipilimumab for untreated, unresectable, pleural mesothelioma: the meso-immune (GFPC 04\u20132021) trial. Lung Cancer 194:107866","journal-title":"Lung Cancer"},{"key":"2706_CR14","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107440","volume":"187","author":"DW Dumoulin","year":"2024","unstructured":"Dumoulin DW, Douma LH, Hofman MM et al (2024) Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma. Lung Cancer 187:107440","journal-title":"Lung Cancer"},{"key":"2706_CR15","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","volume":"19","author":"N McNamee","year":"2023","unstructured":"McNamee N, Harvey C, Gray L et al (2023) Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso. J Thorac Oncol 19:636\u2013642","journal-title":"J Thorac Oncol"},{"key":"2706_CR16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122\u2013133","journal-title":"N Engl J Med"},{"key":"2706_CR17","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833","journal-title":"N Engl J Med"},{"key":"2706_CR18","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379:2108\u20132121","journal-title":"N Engl J Med"},{"key":"2706_CR19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10147-023-02292-3","volume":"28","author":"A Nakamura","year":"2023","unstructured":"Nakamura A, Hashimoto M, Kondo N et al (2023) Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention. Int J Clin Oncol 28:409\u2013415","journal-title":"Int J Clin Oncol"},{"key":"2706_CR20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","volume":"84","author":"MG Zauderer","year":"2014","unstructured":"Zauderer MG, Kass SL, Woo K et al (2014) Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 84:271\u2013274","journal-title":"Lung Cancer"},{"key":"2706_CR21","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, Kijima T, Aoe K et al (2019) Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase ii study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 25:5485\u20135492","journal-title":"Clin Cancer Res"},{"key":"2706_CR22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L et al (2019) Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 20:239\u2013253","journal-title":"Lancet Oncol"},{"key":"2706_CR23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF et al (2018) Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol 13:1569\u20131576","journal-title":"J Thorac Oncol"},{"key":"2706_CR24","volume":"2","author":"N Fujimoto","year":"2021","unstructured":"Fujimoto N, Okada M, Kijima T et al (2021) Clinical efficacy and safety of nivolumab in japanese patients with malignant pleural mesothelioma: 3-year results of the MERIT study. JTO Clin Res Rep 2:100135","journal-title":"JTO Clin Res Rep"},{"key":"2706_CR25","first-page":"ivad173","volume":"38","author":"M Takenaka","year":"2024","unstructured":"Takenaka M, Kuroda K, Yoshimatsu K et al (2024) Salvage pleurectomy\/decortication following immunotherapy for malignant pleural mesothelioma. Interdiscip Cardiovasc Thorac Surg 38:ivad173","journal-title":"Interdiscip Cardiovasc Thorac Surg"},{"key":"2706_CR26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13000-018-0766-0","volume":"13","author":"J Ma","year":"2018","unstructured":"Ma J, Li J, Qian M et al (2018) PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28\u20138 and E1L3N). Diagn Pathol 13:91","journal-title":"Diagn Pathol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02706-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02706-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02706-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T14:59:43Z","timestamp":1743260383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02706-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2706"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02706-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author ha any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}